ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.57 +2.58%

+$0.18 today

Market cap
$6.99B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 11.10M

Average 16.40M

Returns on capital

ImmunityBio, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

70.3%

avg 36.7%

ROIC

-56.9%

avg -76.4%

ROA

-70.0%

avg -74.8%

Analysis

ROE is currently the strongest return metric at 70.3% versus its period average of 36.7%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Richard Gerald Adcock

President, Chief Executive Officer & DirectorUSD 1.58M57——

Patrick Soon-Shiong FRCS

Founder, Executive Chairman and Global Chief Scientific & Medical OfficerUSD 1.15M73——

David C. Sachs

Chief Financial OfficerUSD 902.17K4840.65K<0.01%

Regan J. Lauer

Chief Accounting OfficerUSD 522.49K564.07K<0.01%

Enrique Diloné

Chief Technology Officer—59——

Leonard S. Sender

Chief Medical Officer of Liquid Tumors & Cell Therapy————

Sandeep K. Reddy

Chief Medical Officer————

Sarah Singleton

Chief Communications Officer & Head of Patient Advocacy————

Barry J. Simon

Chief Corporation Affairs Officer & Director—612.78M0.27%

Emily Arison

Senior Vice President of Human Resources————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 5, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

16

$9.51M

Net Transaction Value

−$9.51M

Net selling

Most Active

Simon Barry J.

8 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 5, 26

Simon Barry J.

Direct

Sell$268.8K
Oct 2, 26

Cohen Cheryl

Direct

Sell$851.1K
Jul 2, 26

Cohen Cheryl

Direct

Sell$1.2M
Jul 1, 26

Selecky Christobel

Direct

Sell$1.4M
Jun 30, 26

Selecky Christobel

Direct

Sell$9K
Jun 29, 26

Selecky Christobel

Direct

Sell$862.2K
Jun 24, 26

Simon Barry J.

Direct

Sell$196.9K
Jun 4, 26

Simon Barry J.

Direct

Sell$165.3K
Feb 24, 26

Simon Barry J.

Direct

Sell$900.8K
Feb 23, 26

Selecky Christobel

Direct

Sell$250K

1–10 of 16

Summary

Insiders reported 0 buys worth $0.00 and 16 sells worth $9.51M over the last 12 months. That adds up to net selling of $9.51M. Simon Barry J. was the most active insider with 8 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+678.6%
+86.0% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Recent growth has been strongest in Revenue at +678.6% over three years. Forward estimates point to Revenue at +86.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does ImmunityBio, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about IBRX's management, answered from reported figures.

Who manages IBRX?

ImmunityBio, Inc. (IBRX) lists 10 active executives. The top listed executive is Enrique Diloné, Chief Technology Officer.

Are IBRX insiders buying or selling?

Recent insider activity shows net buying of $563.39M.